Navigation Links
First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418
Date:5/1/2009

BONITA SPRINGS, Fla., May 1 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, announced today that dosing has started in a Phase I clinical trial of GGTI-2418. GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that induces apoptosis by downregulating several pivotal oncogenic and tumor survival pathways.

The Phase I study is led by Dr. Peter O'Dwyer, Professor of Medicine at the University of Pennsylvania School of Medicine and Program Leader of the Experimental Therapeutics Program at the Abramson Cancer Center of the University of Pennsylvania, and by Dr. Gabriela Chiorean, Assistant Professor of Medicine at the Indiana University School of Medicine and a physician/researcher with the Indiana University Melvin and Bren Simon Cancer Center.

"This is the first geranylgeranyltransferase inhibitor to move to clinical phase studies," stated Edmundo Muniz, M.D., Ph.D., President and Chief Executive Officer of Tigris. "Initiation of this Phase I study of GGTI-2418 in these two top Phase I cancer research centers is a significant step in the development of this first-in-class molecule to treat cancer in many different tumor types."

"We are excited to participate in the first study of this novel agent," commented Dr. Chiorean. "The development of a molecule to inhibit the geranylgeranyltransferase pathway would be a significant advancement in cancer treatment."

The primary objective of the Company's Phase I trial with GGTI-2418 is to determine its safety, tolerability, and recommended Phase II dose. Patients with metastatic solid tumors for which standard treatments have failed, or for whom standard therapies are not available, will be evaluated. The number of patients to be enrolled will depend on the number of patient cohorts investigated until dose-limiting toxicity
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 , ... part) in, into or from any jurisdiction where to do ... such jurisdiction.  Shire plc ("Shire" or the "Company") ... article this afternoon.  Shire confirms it has held a meeting ... made by Shire without the prior agreement or approval of ...
(Date:7/11/2014)... July 11, 2014 EPFL and ... the appointment of John P. Donoghue . The ... Geneva . The new Wyss ... in Geneva , has named as ... John P. Donoghue , founder of Brown University,s ...
(Date:7/11/2014)... 11, 2014 Cayenne Medical, Inc., ... in the soft tissue reconstruction segment, announced the ... for surgeries involving the shoulder and extremities. The ... novel, inserter-controlled deployment method. The unique delivery eliminates ... anchor pull-out, or anchor displacement (also commonly know ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6
... Therapeutics, LLC, a biopharmaceutical company focused on the ... a $55 million Series C financing. The financing ... development and healthcare investment firm. The company ... Phase III clinical development program for its lead ...
... widely used drugs, is also one of the trickiest to ... of serious problems when given the standard starting dose. , ... based on genetic information, an international research team has created ... the blood-thinning drug for each patient. , Three University ...
... Corporation (Nasdaq: PMD ) today announced fourth ... December 31, 2008. The Company also announced a ... of record as of March 6, 2009 to be ... the Company,s 50th consecutive quarterly dividend.The Company,s revenue for ...
Cached Biology Technology:Sopherion Therapeutics Secures $55 Million in Series C Funding 2Genetic information personalizes warfarin prescribing 2Genetic information personalizes warfarin prescribing 3Psychemedics Corporation Announces 2008 Year End Results 2Psychemedics Corporation Announces 2008 Year End Results 3Psychemedics Corporation Announces 2008 Year End Results 4Psychemedics Corporation Announces 2008 Year End Results 5
(Date:7/10/2014)... BLUE BELL, Pa. , July 2, 2014  Unisys ... The Netherlands , Unisys Nederland N.V., today announced that ... (DJI) to deliver, implement and manage a new Basic Provision ... . Unisys won the contract with a ... for identity management software. The term of the contract is ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) has ... Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, ... to their offering http://photos.prnewswire.com/prnh/20130307/600769 ... Sensing Market to Grow Exponentially. Touch-less sensing applications ... companies were unable to leverage this technology due ...
(Date:7/10/2014)... 2014  Acuity Market Intelligence today released forecasts from "The ... that the global market for National Electronic ID (eID) programs ... During this time, the number of National eID cards in ... Asia , with its vast population, will dominate ... issued, while Europe trails a distant ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2
... Michigan have found a new potential benefit of a ... proteins in the brain. The aggregation of ... disease and other neurodegenerative conditions., A paper published recently ... Sciences explained how U-M Life Sciences Institute faculty ...
... March 5, 2013 UT Southwestern Medical Center scientists report ... model of an incurable human cancer. "To my knowledge, this ... defined malignant human cancer has been generated in which the formation ... in which blocking the pathway cures the mouse of the tumor," ...
... technology could soon experience a significant upgrade that would ... the development of a new key material by a ... Department of Biomedical Engineering at Texas A&M University. ... signals that can be used to produce an image, ...
Cached Biology News:Green tea extract interferes with the formation of amyloid plaques in Alzheimer's disease 2UT Southwestern scientists make mouse model of human cancer, demonstrate cure 2UT Southwestern scientists make mouse model of human cancer, demonstrate cure 3Texas A&M research contributes to improved ultrasound imaging 2
D.R. Harper (1993) • Includes: essential information on taxonomy, culture and safe handling of viruses, immunology, monoclonal antibodies, antivirals and vaccines....
...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
...
Biology Products: